Terms: = Colorectal cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Treatment
1567 results:
1. Exploring the Key Signaling Pathways and ncRNAs in colorectal cancer.
Lee YJ; Kim WR; Park EG; Lee DH; Kim JM; Shin HJ; Jeong HS; Roh HY; Kim HS
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38674135
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of a novel small-molecule activator of SIRT3 that inhibits cell proliferation and migration by apoptosis and autophagy-dependent cell death pathways in colorectal cancer.
Mou Y; Chen Y; Fan Z; Ye L; Hu B; Han B; Wang G
Bioorg Chem; 2024 May; 146():107327. PubMed ID: 38579616
[TBL] [Abstract] [Full Text] [Related]
3. PI3K/akt/mTOR Signaling Pathway as a Target for colorectal cancer treatment.
Leiphrakpam PD; Are C
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542151
[TBL] [Abstract] [Full Text] [Related]
4. Timing of Surgery and Social Determinants of Health Related to Pathologic Complete Response after Total Neoadjuvant Therapy for Rectal Adenocarcinoma: Retrospective Study of National cancer Database.
Mai M; Goldman J; Appiah D; Abdulrahman R; Kidwell J; Shi Z
Curr Oncol; 2024 Feb; 31(3):1291-1301. PubMed ID: 38534930
[TBL] [Abstract] [Full Text] [Related]
5. Reduced chemokine C-C motif ligand 1 expression may negatively regulate colorectal cancer progression at liver metastatic sites.
Iwata M; Haraguchi R; Kitazawa R; Ito C; Ogawa K; Takada Y; Kitazawa S
J Cell Mol Med; 2024 Apr; 28(7):e18193. PubMed ID: 38506205
[TBL] [Abstract] [Full Text] [Related]
6. Inhibition of PI3K/akt signaling using BKM120 reduced the proliferation and migration potentials of colorectal cancer cells and enhanced cisplatin-induced cytotoxicity.
Khameneh SC; Sari S; Razi S; Yousefi AM; Bashash D
Mol Biol Rep; 2024 Mar; 51(1):420. PubMed ID: 38483663
[TBL] [Abstract] [Full Text] [Related]
7. Inhibition of Multifunctional Protein p32/C1QBP Promotes Cytostatic Effects in Colon cancer Cells by Altering Mitogenic Signaling Pathways and Promoting Mitochondrial Damage.
Egusquiza-Alvarez CA; Moreno-Londoño AP; Alvarado-Ortiz E; Ramos-Godínez MDP; Sarabia-Sánchez MA; Castañeda-Patlán MC; Robles-Flores M
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473963
[TBL] [Abstract] [Full Text] [Related]
8. Role of deubiquitinase JOSD2 in the pathogenesis of esophageal squamous cell carcinoma.
Wang WP; Shi D; Yun D; Hu J; Wang JF; Liu J; Yang YP; Li MR; Wang JF; Kong DL
World J Gastroenterol; 2024 Feb; 30(6):565-578. PubMed ID: 38463028
[TBL] [Abstract] [Full Text] [Related]
9. Regulation of metastatic potential by drug repurposing and mitochondrial targeting in colorectal cancer cells.
Mathur S; Srivastava P; Srivastava A; Rai NK; Abbas S; Kumar A; Tiwari M; Sharma LK
BMC Cancer; 2024 Mar; 24(1):323. PubMed ID: 38459456
[TBL] [Abstract] [Full Text] [Related]
10. Understanding the molecular mechanism responsible for developing therapeutic radiation-induced radioresistance of rectal cancer and improving the clinical outcomes of radiotherapy - A review.
Jain SM; Nagainallur Ravichandran S; Murali Kumar M; Banerjee A; Sun-Zhang A; Zhang H; Pathak R; Sun XF; Pathak S
Cancer Biol Ther; 2024 Dec; 25(1):2317999. PubMed ID: 38445632
[TBL] [Abstract] [Full Text] [Related]
11. Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer.
Liu H; Zhou D; Liu D; Xu X; Zhang K; Hu R; Xiong P; Wang C; Zeng X; Wang L; Zhang S
Cell Death Dis; 2024 Mar; 15(3):187. PubMed ID: 38443386
[TBL] [Abstract] [Full Text] [Related]
12. Broccoli extracellular vesicles enhance the therapeutic effects and restore the chemosensitivity of 5-fluorouracil on colon cancer.
Cao Y; Hou L; Li M; Zhang J; Wang L; Liu C; Luo T; Yan L; Zheng L
Food Chem Toxicol; 2024 Apr; 186():114563. PubMed ID: 38442787
[TBL] [Abstract] [Full Text] [Related]
13. CSF1R inhibition reprograms tumor-associated macrophages to potentiate anti-PD-1 therapy efficacy against colorectal cancer.
Lv Q; Zhang Y; Gao W; Wang J; Hu Y; Yang H; Xie Y; Lv Y; Zhang H; Wu D; Hu L; Wang J
Pharmacol Res; 2024 Apr; 202():107126. PubMed ID: 38432446
[TBL] [Abstract] [Full Text] [Related]
14. Andrographolide sensitizes KRAS-mutant colorectal cancer cells to cetuximab by inhibiting the EGFR/akt and PDGFRβ/akt signaling pathways.
Liu YF; Feng ZQ; Chu TH; Yi B; Liu J; Yu H; Xue J; Wang YJ; Zhang CZ
Phytomedicine; 2024 Apr; 126():155462. PubMed ID: 38394734
[TBL] [Abstract] [Full Text] [Related]
15. Diallyl disulfide induces DNA damage and growth inhibition in colorectal cancer cells by promoting POU2F1 ubiquitination.
Xia L; Lin J; Peng M; Jiang X; Peng Q; Cui S; Zhang W; Li S; Wang J; Oyang L; Tan S; Hu Z; Wu N; Tang Y; Luo X; Ren Z; Shi Y; Liao Q; Zhou Y
Int J Biol Sci; 2024; 20(4):1125-1141. PubMed ID: 38385081
[TBL] [Abstract] [Full Text] [Related]
16. A free fatty acid receptor agonist inducing autophagy in HT-29 cells by downregulating the akt/mTOR signaling pathway.
Hoveizi E; Rafienia B; Shahriari A
J Cancer Res Ther; 2023 Oct; 19(7):1931-1938. PubMed ID: 38376299
[TBL] [Abstract] [Full Text] [Related]
17. Villosol reverses 5-FU resistance in colorectal cancer by inhibiting the CDKN2A gene regulated TP53-PI3K/akt signaling axis.
Chen H; Deng J; Hou TW; Shan YQ
J Ethnopharmacol; 2024 May; 325():117907. PubMed ID: 38342156
[TBL] [Abstract] [Full Text] [Related]
18. Negative Hyperselection of Resistance Mutations for Panitumumab Maintenance in RAS Wild-Type Metastatic colorectal cancer (PanaMa Phase II Trial, AIO KRK 0212).
Stahler A; Kind AJ; Sers C; Mamlouk S; Müller L; Karthaus M; Fruehauf S; Graeven U; Fischer von Weikersthal L; Sommerhäuser G; Kasper S; Hoppe B; Kurreck A; Held S; Heinemann V; Horst D; Jarosch A; Stintzing S; Trarbach T; Modest DP
Clin Cancer Res; 2024 Apr; 30(7):1256-1263. PubMed ID: 38289994
[TBL] [Abstract] [Full Text] [Related]
19. In vitro and in vivo anti-colorectal cancer effect of the newly synthesized sericin/propolis/fluorouracil nanoplatform through modulation of PI3K/akt/mTOR pathway.
Diab SE; Tayea NA; Elwakil BH; Elshewemi SS; Gad AAEM; Abdulmalek SA; Ghareeb DA; Olama ZA
Sci Rep; 2024 Jan; 14(1):2433. PubMed ID: 38286826
[TBL] [Abstract] [Full Text] [Related]
20. The CSF-1R inhibitor pexidartinib affects FLT3-dependent DC differentiation and may antagonize durvalumab effect in patients with advanced cancers.
Voissière A; Gomez-Roca C; Chabaud S; Rodriguez C; Nkodia A; Berthet J; Montane L; Bidaux AS; Treilleux I; Eberst L; Terret C; Korakis I; Garin G; Pérol D; Delord JP; Caux C; Dubois B; Ménétrier-Caux C; Bendriss-Vermare N; Cassier PA
Sci Transl Med; 2024 Jan; 16(731):eadd1834. PubMed ID: 38266104
[TBL] [Abstract] [Full Text] [Related]
[Next]
